Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 19, 2026
Context: Announcement of US FDA approval for Wegovy® HD (semaglutide 7.2 mg), a higher-dose injectable for weight management, awarded a Commissioner’s National Priority Voucher.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a regulatory announcement regarding product approval rather than a financial results report.
Material Changes and Product Milestones
- Regulatory Approval: US FDA approved Wegovy® HD (semaglutide 7.2 mg) for reducing excess body weight and maintaining weight reduction long-term.
- Accelerated Review: Received a Commissioner’s National Priority Voucher, underscoring its role in addressing critical US national health priorities.
- Launch Timeline: Expected US launch in April 2026 as a single-dose pen.
- Global Status: Already approved in the EU and UK; regulatory decisions for the single-dose pen in these regions expected in the second half of 2026.
Clinical Data and Management Commentary
STEP UP Trial Results
| Study | Population | Mean Weight Loss (Efficacy Estimand) | Key Categorical Outcome |
|---|---|---|---|
| STEP UP | Obesity | 20.7% | 31.2% achieved ≥25% weight loss |
| STEP UP T2D | Obesity + Type 2 Diabetes | 14.1% | 21.3% achieved ≥20% weight loss |
Safety Profile: Reaffirmed as well-known and comparable to previous semaglutide trials for weight management.
Management Commentary: CEO Mike Doustdar stated that Wegovy® HD introduces a new offering providing approximately 21% weight loss, complementing the existing 2.4 mg injection and the recently launched Wegovy® pill. The company aims to support healthier lives for people living with obesity.
Investor Verification Checklist
- Verify the commercial launch date of Wegovy® HD in the US (stated as April 2026).
- Monitor regulatory timelines for the single-dose pen approval in the EU and UK (expected H2 2026).
- Assess the impact of the Commissioner’s National Priority Voucher on future regulatory pathways for other products.
- Review upcoming financial reports for revenue recognition related to the new 7.2 mg dose.
- Confirm supply chain readiness for the single-dose pen format.